---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-015239"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:15:48.863248+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Esperion Q2 net loss $43.7M; NEXLETOL/NEXLIZET net product revenue $10.6M up 67% QoQ

## Summary
- U.S. net product revenue $10.6M, up 67% sequentially; prescriptions grew 28% during quarter.
- Net loss $43.7M ($1.67/share) vs net income $124.6M in Q2 2020 on decline in milestone revenue.
- Total revenue $40.7M (vs $212.2M Q2 2020); collaboration revenue fell due to lack of milestone payments.
- Cash $219.2M at June 30; 2021 full-year operating expense guidance $320M-$340M.
- Director Daniel Janney resigned effective July 28; Nicole Vitullo appointed to Audit Committee.

## SEC filing metadata
- accession: 0001628280-21-015239
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/0001628280-21-015239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/espr-20210728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-015239
- JSON: https://secwatch.observer/filing/0001628280-21-015239.json
- Plain text: https://secwatch.observer/filing/0001628280-21-015239.txt

## Key facts
- Executive change
  Daniel Janney resigned as Director at Esperion Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On July 28, 2021, Daniel Janney notified the Board of Directors of the Company of his decision to resign from the Company’s Board of Directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/0001628280-21-015239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.